CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: December 21, 2020
Result type: Reports
Project Number: SR0665-000
Product Line: Reimbursement Review

Generic Name: patiromer

Brand Name: Veltassa

Manufacturer: Otsuka Canada Pharmaceuticals Inc.

Therapeutic Area: Hyperkalemia, adults (chronic kidney disease)

Indications: For the treatment of hyperkalemia in adults with chronic kidney disease (eGFR ≥15mL/min/1.73m).

Manufacturer Requested Reimbursement Criteria1: For the treatment of hyperkalemia in adults with CKD 3-4 on RAASi therapy.

Submission Type: Initial

NOC Status at Filing: Post NOC

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openOctober 02, 2020
Call for patient/clinician input closedNovember 23, 2020

- Patient input submission received from the The Kidney Foundation of Canada

Submission receivedOctober 30, 2020
Submission acceptedNovember 13, 2020
Review initiatedNovember 16, 2020
Draft CADTH review report(s) provided to sponsor for commentFebruary 25, 2021
Deadline for sponsors commentsMarch 08, 2021
CADTH responses on draft review report(s) provided to sponsorApril 09, 2021
Expert committee meeting (initial)April 21, 2021
Draft recommendation issued to sponsorMay 03, 2021
May 05, 2021